Highlights of ASH in the Mediterranean, Middle East, and North Africa

Join the world’s leading hematology experts at Highlights of ASH in the Mediterranean, Middle East, and North Africa, a two-day program that highlights the most influential research presented at the latest ASH annual meeting, the premier event in malignant and non-malignant hematology. April 4-5, 2025 Hyatt Regency Casablanca, Casablanca, Morocco By attending Highlights of ASH, you will get a comprehensive review of significant scientific updates in clinical and translational hematologic research, learn

Read the full article here

Source: www.hematology.org

Categories: Oncologists1, General Medicine News

Tags: hematology,ASH24,MedTwitter

Tweets with this article

ASH

Join the world's leading #hematology experts at Highlights of ASH in the Mediterranean, Middle East, and North Africa! 🌍 Discover the most practice-changing research from #ASH24 with takeaways tailored to the region. Register: https://t.co/2IOpZsoZBE #MedTwitter https://t.co/lfAx3Wxp5U

Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC

Frontline treatment with datopotamab deruxtecan plus durvalumab with/without carboplatin proved active in advanced NSCLC without actionable alterations.

OncLive.com March 10, 2025

Home

Activity Overview

Medscape Oncology March 10, 2025

Professor, author suggests ‘gaming cancer’ can help accelerate oncology research

As Jeff Yoshimi, PhD, wrote his book about how video games could improve scientific literacy on cancer and generate ideas that could eventually lead to…

HemOnc Today March 10, 2025

Breaking the mold: Unconventional T cells in cancer therapy

Unconventional T cells, including invariant natural killer T (iNKT) cells, gamma delta (γδ) T cells, and mucosal-associated invariant T (MAIT) cells, play important roles in both innate…

Cancer Cell March 10, 2025

Study Highlights Unique Needs of Young Adults with Colorectal Cancer

Published: November 13, 2024Written by: Dana-Farber Editorial TeamClinicians and researchers have recognized a disturbing trend in recent years: colorectal cancer (CRC) in young people is…

Dana-Farber March 10, 2025

Home

Activity Overview

Medscape Oncology March 10, 2025

Participation in Electronic Patient-Reported Outcome Measures Collection as a Part of Routine Supportive Care Delivery in Oncology | JCO Oncology Practice

PURPOSEThe use of electronic patient-reported outcome measures (ePROMs) in supportive cancer care can lead to benefits, such as identifying at-risk patients in need of closer…

J Oncology Practice March 10, 2025

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

PURPOSEThe standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. The randomized, double-blind, phase…

ASCO Publications March 10, 2025

Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor–Positive Early Breast Cancer: A Nationwide Cohort Study

PURPOSEYoung age is associated with increased risk of recurrence in hormone receptor (HR)–positive early-stage breast cancer (eBC). Lack of adherence to endocrine therapy (ET) is…

ASCO Publications March 10, 2025

What are the next steps after unsuccessful immunotherapy in RCC?

Maria Bourlon, MD, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico discusses the treatment of patients with renal cell carcinoma (RCC)…

VJ Oncology March 10, 2025

Related Articles